Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving argenx SE and its officers or directors [1] Group 1: Regulatory Concerns - On June 30, 2025, the FDA issued an alert regarding argenx's Vyvgart Hytrulo product, indicating a potential risk of severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy [3] - Following the FDA alert, argenx's American Depositary Share (ADS) price decreased by $8.92, or 1.59%, closing at $551.22 per ADS on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is actively seeking investors of argenx to discuss potential claims related to the investigation [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Following these disclosures, XPLR's unit price fell $3.97 per unit, or 25.13%, to close at $11.83 per unit on January 28, 2025. XPLR's unit price continued to fall an additional $1.39 per unit, or 11.75%, over the following two consecutive trading sessions, to close at $10.44 per unit on January 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving American Outdoor Brands, Inc. and its officers or directors [1] Financial Performance - On June 26, 2025, American Outdoor reported its financial results for Q4 and the full fiscal year 2025, revealing that retailers accelerated orders, pulling forward an estimated $8 million to $10 million in sales from the upcoming fiscal year [3] - The company announced the suspension of its fiscal 2026 guidance due to uncertainties surrounding tariffs [3] Stock Market Reaction - Following the announcement of the financial results and guidance suspension, American Outdoor's stock price dropped by $1.57 per share, or 13.13%, closing at $10.39 per share on June 27, 2025 [4]

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. (“Lineage” or the “Company”) (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Lineage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around July 25 ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - On July 9, 2025, Ultragenyx and Mereo BioPharma Group announced the progress of the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [3] - Following the announcement, Ultragenyx's stock price dropped by $10.41, or 25.11%, closing at $31.04 per share on July 10, 2025 [3] Group 2 - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having pioneered the field of securities class actions over 80 years ago [4] - The firm has a history of recovering multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Abacus Global Management, Inc. [1] Group 1: Investigation Details - The investigation is focused on whether Abacus and its officers or directors have engaged in fraudulent activities [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1] Group 2: Allegations Against Abacus - A report by Morpheus Research claims that Abacus has manipulated its portfolio valuation methodology to present a misleadingly profitable image [3] - The report also criticizes Abacus's life expectancy estimation methods and highlights historical concerns regarding its co-founders [3] Group 3: Market Reaction - Following the release of the allegations, Abacus's stock price dropped by $1.64, or 21.47%, closing at $6.00 per share on June 5, 2025 [4]

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CTO Realty Growth, Inc.  (“CTO” or the “Company”) (NYSE: CTO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CTO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 25, 2025, ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Edgewise Therapeutics and its officers or directors [1] Group 1: Company Performance - On June 26, 2025, Edgewise reported clinical trial data for its lead asset, sevasemten, targeting Becker and Duchenne muscular dystrophies, which it described as "positive" [3] - Despite the positive characterization, the U.S. FDA indicated that the CANYON data was insufficient for accelerated approval during a Type C meeting [3] - Following this announcement, Edgewise's stock price decreased by $1.27 per share, or 8.86%, closing at $14.33 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Edgewise regarding claims of potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Caleres reported a first-quarter 2025 sales figure of $614.2 million, which is a 6.8% decline year-over-year, and the CFO acknowledged this was below expectations [3] - Following the disappointing financial results, Caleres's stock price dropped by $3.00 per share, or 18.32%, closing at $13.38 per share on May 29, 2025 [3] - The company has suspended its guidance for 2025 due to uncertainty in the business environment [3] Company Overview - Caleres, Inc. is a publicly traded company listed on the NYSE under the ticker symbol CAL [1] - The company is currently facing scrutiny from investors and legal investigations related to its business practices [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving American Outdoor Brands, Inc. and its officers or directors [1] Financial Performance - On June 26, 2025, American Outdoor reported its financial results for Q4 and the full fiscal year 2025, revealing that retailers accelerated orders, pulling forward an estimated $8 million to $10 million in sales from the upcoming fiscal year [3] - The company announced the suspension of its fiscal 2026 guidance due to uncertainties surrounding tariffs [3] Stock Market Reaction - Following the financial results announcement, American Outdoor's stock price dropped by $1.57 per share, or 13.13%, closing at $10.39 per share on June 27, 2025 [4]